Summary
Global Markets Direct’s, ‘Peripheral Neuropathic Pain - Pipeline Review, H1 2016’, provides an overview of the Peripheral Neuropathic Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain
- The report reviews pipeline therapeutics for Peripheral Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Achelios Therapeutics, Inc.
AnaBios Corporation
Chromocell Corporation
Eli Lilly and Company
GW Pharmaceuticals Plc
Nektar Therapeutics
Phosphagenics Limited
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Zynerba Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral Neuropathic Pain Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral Neuropathic Pain - Overview 9
Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis 10
Peripheral Neuropathic Pain - Therapeutics under Development by Companies 11
Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 12
Peripheral Neuropathic Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral Neuropathic Pain - Products under Development by Companies 16
Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes 17
Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development 18
Achelios Therapeutics, Inc. 18
AnaBios Corporation 19
Chromocell Corporation 20
Eli Lilly and Company 21
GW Pharmaceuticals Plc 22
Nektar Therapeutics 23
Phosphagenics Limited 24
Spherium Biomed S.L. 25
Sunovion Pharmaceuticals Inc. 26
Zynerba Pharmaceuticals, Inc. 27
Peripheral Neuropathic Pain - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AXPN-03 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CC-8464 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DSP-2230 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
duloxetine hydrochloride DR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ECL-1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ketoprofen - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nabiximols - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NKTR-171 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
oxycodone ER - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule for Pain - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SP-15001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ZYN-001 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Peripheral Neuropathic Pain - Recent Pipeline Updates 57
Peripheral Neuropathic Pain - Dormant Projects 66
Peripheral Neuropathic Pain - Discontinued Products 67
Peripheral Neuropathic Pain - Product Development Milestones 68
Featured News & Press Releases 68
Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch 68
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Peripheral Neuropathic Pain, H1 2016 9
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H1 2016 18
Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H1 2016 19
Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H1 2016 20
Peripheral Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016 21
Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016 22
Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2016 23
Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H1 2016 24
Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H1 2016 25
Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 26
Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Peripheral Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016 57
Peripheral Neuropathic Pain - Dormant Projects, H1 2016 66
Peripheral Neuropathic Pain - Discontinued Products, H1 2016 67
List of Figures
Number of Products under Development for Peripheral Neuropathic Pain, H1 2016 9
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Top 10 Targets, H1 2016 29
Number of Products by Stage and Top 10 Targets, H1 2016 29
Number of Products by Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35
